日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immunoprecipitation-mass spectrometry reveals known and novel (NatC, BCS1L) antinuclear antibodies in rheumatoid arthritis

免疫沉淀-质谱分析揭示了类风湿性关节炎中已知的和新的(NatC、BCS1L)抗核抗体

De Leeuw, Jonas; Michiels, Birthe; Derua, Rita; Vulsteke, Jean-Baptiste; Dillaerts, Doreen; Cockx, Maaike; Verschueren, Patrick; Bossuyt, Xavier

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

一线乐伐替尼联合帕博利珠单抗对比化疗治疗晚期子宫内膜癌:一项随机、开放标签的III期试验

Marth, Christian; Moore, Richard G; Bidziński, Mariusz; Pignata, Sandro; Ayhan, Ali; Rubio, M Jesús; Beiner, Mario; Hall, Marcia; Vulsteke, Christof; Braicu, Elena Ioana; Sonoda, Kenzo; Wu, Xiaohua; Frentzas, Sophia; Mattar, André; Lheureux, Stephanie; Chen, Xiaojun; Hasegawa, Kosei; Magallanes-Maciel, Manuel; Choi, Chel Hun; Shalkova, Mariia; Kaen, Diego; Wang, Peng-Hui; Berger, Regina; Okpara, Chinyere E; McKenzie, Jodi; Yao, Lili; Orlowski, Robert; Khemka, Vivek; Gilbert, Lucy; Makker, Vicky

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors

对于新诊断的高危子宫内膜癌,帕博利珠单抗或安慰剂联合辅助化疗(伴或不伴放疗)可导致错配修复缺陷型肿瘤

Slomovitz, Brian M; Cibula, David; Lv, Weiguo; Ortaç, Fırat; Hietanen, Sakari; Backes, Floor; Kikuchi, Akira; Lorusso, Domenica; Dańska-Bidzińska, Anna; Samouëlian, Vanessa; Barretina-Ginesta, Maria-Pilar; Vulsteke, Christof; Lai, Chyong-Huey; Pothuri, Bhavana; Zhang, Yu; Magallanes-Maciel, Manuel; Amit, Amnon; Guarneri, Valentina; Zagouri, Flora; Bell, Maria; Welz, Julia; Eminowicz, Gemma; Hruda, Martin; Willmott, Lyndsay J; Lichfield, Jasmine; Wang, Wei; Orlowski, Robert; Aktan, Gursel; Gladieff, Laurence; Van Gorp, Toon

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

EV-302 的探索性亚组分析:一项评估恩福妥单抗联合帕博利珠单抗与化疗治疗既往未接受治疗的局部晚期或转移性尿路上皮癌的 III 期全球研究

van der Heijden, M S; Powles, T; Gupta, S; Loriot, Y; Galsky, M D; Valderrama, B P; Sridhar, S S; Yu, E Y; Iyer, G; Kikuchi, E; Castellano, D; Hoffman-Censits, J; Drakaki, A; Mar, N; Maroto Rey, J P; Vulsteke, C; Arafat, W; Duran, I; Dawson, N A; Swami, U; Gorla, S; Moreno, B H; Yu, X; Lu, Y-T; Bedke, J

A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

TROPiCS-04 研究的简明语言摘要:在接受铂类化疗和免疫治疗后,使用 sacituzumab govitecan 治疗局部晚期或转移性膀胱癌、尿道癌或上尿路癌患者。

Powles, Thomas; Tagawa, Scott T; Vulsteke, Christof; Gross-Goupil, Marine; Park, Se Hoon; Necchi, Andrea; De Santis, Maria; Duran, Ignacio; Morales-Barrera, Rafael; Guo, Jun; Sternberg, Cora N; Bellmunt, Joaquim; Goebell, Peter J; Kovalenko, Maria; Boateng, Freda; Sierecki, Mitch; Wang, Lu; Sima, Camelia S; Waldes, Jana; Bangs, Rick; Loriot, Yohann; Grivas, Petros

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

对接受免疫检查点抑制剂治疗的转移性肾细胞癌患者,最佳治疗持续时间是多久?我们应该治疗超过两年吗?

Decruyenaere, Alexander; Christine, Gennigens; Sylvie, Rottey; Annouschka, Laenen; Seront, Emmanuel; Everaert, Els; Debruyne, Philip R; Van Den Bulck, Heidi; Bastin, Julie; Annelies, Verbiest; Vulsteke, Christof; Schatteman, Peter; Luyten, Daisy; Aspeslagh, Sandrine; Martinez-Chanza, Nieves; De Bock, Marlies; Meyskens, Thomas; Verheezen, Jolanda; Brouwers, Barbara; Beuselinck, Benoit

Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data

免疫检查点抑制剂治疗癌症患者的心血管毒性:基于比利时医院数据的自然语言处理多中心研究

Delombaerde, D; Oeste, C L; Geldhof, V; Croes, L; Bassez, I; Verbiest, A; Tack, L; Hens, D; Franssen, C; Debruyne, P R; Prenen, H; Peeters, M; De Sutter, J; Vulsteke, C

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

尼拉帕尼一线维持治疗新诊断的晚期卵巢癌患者:PRIMA/ENGOT-OV26/GOG-3012试验的最终总生存期结果

Monk, B J; Barretina-Ginesta, M P; Pothuri, B; Vergote, I; Graybill, W; Mirza, M R; McCormick, C C; Lorusso, D; Moore, R G; Freyer, G; O'Cearbhaill, R E; Heitz, F; O'Malley, D M; Redondo, A; Shahin, M S; Vulsteke, C; Bradley, W H; Haslund, C A; Chase, D M; Pisano, C; Holman, L L; Pérez, M J Rubio; DiSilvestro, P; Gaba, L; Herzog, T J; Bruchim, I; Compton, N; Shtessel, L; Malinowska, I A; González-Martín, A

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

肿瘤突变负荷和PD-L1与帕博利珠单抗联合或不联合化疗治疗晚期尿路上皮癌疗效的相关性

Fléchon, Aude; Morales-Barrera, Rafael; Powles, Thomas; Alva, Ajjai; Özgüroğlu, Mustafa; Csöszi, Tibor; Loriot, Yohann; Rodriguez-Vida, Alejo; Géczi, Lajos; Cheng, Susanna Y; Fradet, Yves; Oudard, Stéphane; Vulsteke, Christof; Gunduz, Seyda; Mamtani, Ronac; Yu, Evan Y; Montesa Pino, Alvaro; Anido, Urbano; Sendur, Mehmet A N; Gravis, Gwenaelle; Révész, János; Kostorov, Vladimir; Huillard, Olivier; Ma, Junshui; Rajasagi, Mohini; Vajdi, Amir; Lunceford, Jared; Cristescu, Razvan; Imai, Kentaro; Homet Moreno, Blanca; Matsubara, Nobuaki

A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer

一项针对进展性、转移性、去势抵抗性前列腺癌患者的 AZD4635 联合度伐利尤单抗和卡巴他赛的 II 期研究 (AARDVARC)

Alonso-Gordoa, T; Goodman, M; Vulsteke, C; Roubaud, G; Zhang, J; Parikh, M; Piulats, J M; Azaro, A; James, G D; Cavazzina, R; Gangl, E T; Thompson, J; Pouliot, G; Kumar, R; Sweeney, C